These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8448736)

  • 1. Treatment of carcinoma of the esophagus with 5-fluorouracil and recombinant alfa-2a-interferon.
    Wadler S; Fell S; Haynes H; Katz HJ; Rozenblit A; Kaleya R; Wiernik PH
    Cancer; 1993 Mar; 71(5):1726-30. PubMed ID: 8448736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
    Ilson DH; Sirott M; Saltz L; Heelan R; Huang Y; Keresztes R; Kelsen DP
    Cancer; 1995 May; 75(9):2197-202. PubMed ID: 7712428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II clinical trial with 5-fluorouracil, recombinant interferon-alpha-2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus.
    Wadler S; Haynes H; Beitler JJ; Hu X; Fell S; Camacho M; Levine B; Wiernik PH
    Cancer; 1996 Jul; 78(1):30-4. PubMed ID: 8646722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I-II study of 5-fluorouracil, recombinant interferon alpha2a, and cisplatin in combination with external beam radiation therapy followed by surgery in patients with locally advanced carcinoma of the esophagus.
    Damle S; Beitler JJ; Haynes H; Camacho M; Wolf E; Wadler S
    Am J Clin Oncol; 1999 Aug; 22(4):391-5. PubMed ID: 10440197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
    Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
    J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II clinical trial of 13-cis-retinoic acid and interferon-alpha-2a in patients with advanced esophageal carcinoma.
    Enzinger PC; Ilson DH; Saltz LB; Martin LK; Kelsen DP
    Cancer; 1999 Mar; 85(6):1213-7. PubMed ID: 10189124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study.
    Wadler S; Lembersky B; Atkins M; Kirkwood J; Petrelli N
    J Clin Oncol; 1991 Oct; 9(10):1806-10. PubMed ID: 1919631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot trial of combination cisplatin, 5-fluorouracil and interferon-alpha in the treatment of advanced esophageal carcinoma.
    Bazarbashi S; Rahal M; Raja MA; El Weshi A; Pai C; Ezzat A; Ajarim D; Memon M; Al Fadda M
    Chemotherapy; 2002 Sep; 48(4):211-6. PubMed ID: 12218269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon alfa-2a and fluorouracil in the treatment of patients with advanced esophageal cancer.
    Kelsen D; Lovett D; Wong J; Saltz L; Buckley M; Murray P; Heelan R; Lightdale C
    J Clin Oncol; 1992 Feb; 10(2):269-74. PubMed ID: 1732428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II/pharmacodynamic trial of dose-intensive, weekly parenteral hydroxyurea and fluorouracil administered with interferon alfa-2a in patients with refractory malignancies of the gastrointestinal tract.
    Wadler S; Damle S; Haynes H; Kaleya R; Schechner R; Berkenblit R; Ladner RD; Murgo A
    J Clin Oncol; 1999 Jun; 17(6):1771-8. PubMed ID: 10561214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of N-(phosphonacetyl)-L-aspartate (PALA), 5-fluorouracil and recombinant interferon-alpha-2b in patients with advanced gastric carcinoma.
    Wadler S; Gleissner B; Hilgenfeld RU; Thiel E; Haynes H; Kaleya R; Rozenblit A; Kreuser ED
    Eur J Cancer; 1996 Jun; 32A(7):1254-6. PubMed ID: 8758262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-Fluorouracil plus interferon alpha-2a compared to 5-fluorouracil alone in the treatment of advanced colon carcinoma: a multicentric randomized study.
    Palmeri S; Meli M; Danova M; Bernardo G; Leonardi V; Dastoli G; Rausa L; Russo A; Filippelli G; Palmieri G; Russo A; Della Vittoria Scarpati M; Lo Russo V; Di Lauro L; Colucci G; Bruni G; Piazzi M; Gebbia N; Spada S
    J Cancer Res Clin Oncol; 1998; 124(3-4):191-8. PubMed ID: 9619746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma.
    Wadler S; Schwartz EL; Goldman M; Lyver A; Rader M; Zimmerman M; Itri L; Weinberg V; Wiernik PH
    J Clin Oncol; 1989 Dec; 7(12):1769-75. PubMed ID: 2585018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991.
    Wadler S; Atkins M; Karp D; Neuberg D; Haynes H; Dutcher JP
    Cancer J Sci Am; 1998; 4(4):261-8. PubMed ID: 9689985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
    Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
    Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma.
    Pazdur R; Ajani JJ; Abbruzzese JL; Belt RJ; Dakhil SR; Dubovsky D; Graham S; Pilat S; Winn R; Levin B
    Cancer; 1992 Oct; 70(8):2073-6. PubMed ID: 1394037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of 5-fluorouracil, leucovorin, interferon-alpha-2a, and cisplatin as neoadjuvant chemotherapy for locally advanced esophageal carcinoma.
    Temeck BK; Liebmann JE; Theodossiou C; Steinberg SM; Cook JA; Metz DC; Shawker TH; Allegra CJ; Russo A; Pass HI
    Cancer; 1996 Jun; 77(12):2432-9. PubMed ID: 8640689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of high-dose infusional hydroxyurea, high-dose infusional 5-fluorouracil and recombinant interferon-alpha-2a in patients with advanced malignancies.
    Wadler S; Haynes H; Schechner R; Rozenblit A; Wiernik PH
    Invest New Drugs; 1996; 13(4):315-20. PubMed ID: 8824349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bimonthly high dose leucovorin and 5-fluorouracil 48-hour infusion with interferon-alpha-2a in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
    Tournigand C; Louvet C; de Gramont A; Lucchi E; Seitz JF; Mal F; Raymond E; Cady J; Carola E; Krulik M
    Cancer; 1997 Mar; 79(6):1094-9. PubMed ID: 9070485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2A: results of a phase II trial.
    Bernhard H; Jäger-Arand E; Bernhard G; Heike M; Klein O; Riemann JF; Meyer zum Büschenfelde KH; Dippold W; Knuth A
    Br J Cancer; 1995 Jan; 71(1):102-5. PubMed ID: 7819023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.